Researchers at Baylor College of Medicine have identified four new protein markers that improve detection of triple-negative breast cancer cells in blood, potentially enhancing the accuracy of liquid biopsy tests, according to a recent study.
Coverage marks a step in expanding access to ultra-sensitive molecular residual disease detection for breast cancer patients.
A new editorial discusses findings from the COMET trial, suggesting that early-stage breast cancer may not require immediate surgery.
Many breast cancer survivors who qualify for genetic testing are not receiving it, though those who do often discuss results with family.
Read More
A new blood test can predict the recurrence of breast cancer in high-risk patients by detecting cancer DNA months or years before relapse.
Read More
PreciseDx will present findings on their AI-driven breast cancer recurrence prediction test at the 2024 ASCO Annual Meeting.
Read More
This collaborative study seeks to represent a significant step forward in digital pathology and oncology breast cancer research
Read More
Bio-Rad Laboratories launched its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit.Â
Read More
BCI testing is reshaping treatment decisions for early-stage HR+ breast cancer patients by helping guide endocrine therapy choices.
Read More
The AidaBreast novel biosignature also predicts radiation therapy benefit for early-stage invasive breast cancer patients.
Read More
For patients with metastatic HR+ breast cancer, there may be no test more important than monitoring for an ESR1 mutation.
Read More
Scientists developed a saliva test that screens for breast cancer, which is showing promising results in experimental testing.
Read More
The commonly ordered biomarker test is used to guide doctor’s recommendations for patients with estrogen receptor-positive breast cancer.
Read More
A new test uses AI to see whether a patient is positive for cancer as soon as detectable by mammogram or earlier, and before symptoms arise.
Read More
Though breast cancer rates for men are much lower, it is estimated that in 2023, about 2,800 men will be diagnosed with breast cancer.
Read More
Exai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.Â
Read More
DNADX utilizes sequencing DNA data from tumor tissue or plasma circulating tumor DNA to classify breast cancer into four subtypes or clusters.
Read More
PreciseBreast, an AI-powered digital morphology tool, has a fast turnaround time and is cost-effective compared to gene expression tests.
Read More